X

Drug Profile

Picibanil - Chugai Pharmaceutical

Alternative Names: NSC B116209; OK-432; PCB 45; Picibanil

Latest Information Update: 05 Nov 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chugai Pharmaceutical
Class Adjuvants; Antineoplastics; Bacteria; Biological factors; Cell therapies
Mechanism of Action Immunostimulants; Toll-like receptor 4 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Lymphangioma; Malignant ascites; Pleural effusion

Most Recent Events

31 Oct 2002 Chugai Pharmaceutical has been acquired by Roche
15 Oct 2002 A study has been added to the Cancer therapeutic trials section
08 Aug 2001 Launched for Cancer in Taiwan (Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com